UK Markets closed

Brainstorm Cell Therapeutics Inc. (BCLI)

NasdaqCM - NasdaqCM Delayed price. Currency in USD
Add to watchlist
4.09-0.10 (-2.43%)
At close: 4:00PM EDT
People also watch
Full screen
Previous close4.19
Bid4.02 x 1500
Ask4.74 x 1000
Day's range4.05 - 4.16
52-week range2.06 - 5.18
Avg. volume97,806
Market cap77.07M
PE ratio (TTM)-15.15
EPS (TTM)-0.27
Earnings date13 Nov 2017 - 17 Nov 2017
Dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est9.00
Trade prices are not sourced from all markets
  • Zacks Small Cap Researchlast month

    BCLI: Phase 3 Trial of NurOwn® to Initiate Soon

    On August 14 2017, BrainStorm (BCLI) announced financial results for the second quarter of 2017. As expected, the company did not report any revenue. The increase was due to an increase in payroll and stock-based compensation partially offset by a decrease in costs related to the U.S. clinical trial.

  • ACCESSWIRElast month

    Investor Network: Brainstorm Cell Therapeutics Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 16, 2017 / Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI ) will be discussing their earnings results in their Q2 Earnings Call to be held August 16, 2017 at 8:30 AM ...

  • PR Newswirelast month

    BrainStorm Announces Second Quarter 2017 Financial Results

    Conference Call with Management to Discuss Recent Progress Wednesday, August 16, 2017 @ 8:30am Eastern Time HACKENSACK, N.J. and PETACH TIKVAH, Israel , Aug. 15, 2017 /PRNewswire/ -- BrainStorm Cell Therapeutics ...

By using Yahoo, you agree that we and our partners may use cookies for purposes such as customising content and advertising. See our Privacy Policy to learn more; Yahoo is now part of ‘Oath’ and a member of the Verizon family of companies. As of 15 September 2017, we plan to share some user information within our new family. Learn more